> ## Content Index
> Fetch the complete content index at: https://www.nrdlplus.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# ▶️Navigating China’s Multi-Level Coverage Framework: Insights from the C-List Strategy Panel
- URL: https://www.nrdlplus.com/navigating-chinas-multi-level-coverage-framework-insights-from-the-c-list-strategy-panel/
- Published: 2025-07-18T11:00:32.000Z
- Updated: 2026-03-03T20:11:10.000Z
- Description: Industry leaders unpack China’s evolving multi-level coverage system—what the dual-list means for pricing risk, NRDL vs. commercial access, and long-term strategy in the C-List era.
- Author: Kelly Ke
- Tags: Commercial Health Insurance & C-List Dynamics, Coverage & Funding Pathways, C-List Masterclass

[![](https://storage.ghost.io/c/15/10/1510052f-01d9-45db-bfd3-6cc3e958312c/content/images/2025/11/Access360-Subscription-1-1.png)](https://www.nrdlplus.com/archive)

In this C-List Masterclass live strategy panel, our panelists engaged in a dynamic discussion on the evolving access landscape in China, exploring key strategic questions:

**1\. Why traditional affordability levers fall short in China**  
Why is an integrated, system-level view of access critical—not only for success in China, but for optimizing global portfolio performance?

**2\. Assessing pricing risk in China**  
What’s changing in China’s pricing environment? What should global firms consider as they reassess market potential and pricing strategy?

**3\. Pathway dynamics and strategic choices**

- How does the final dual-list workplan depart from the original C-List proposal—and what do those changes reveal about policy direction and strategic considerations for pricing and go-to-market planning?
- NRDL vs. commercial pathways: Can commercial health insurance in China play a meaningful role in staged access strategies?
- Navigating Huiminbao delisting risks in the C-List era: practical short-term responses and long-term repositioning strategies for foreign brands
- Life cycle management and evidence strategy: how to strategically position products across NRDL and commercial pathways for long-term access optimization

[![](https://storage.ghost.io/c/15/10/1510052f-01d9-45db-bfd3-6cc3e958312c/content/images/2025/07/Strategy-Panel-Thumnail-5.png)](https://www.nrdlplus.com/c-list-masterstrategy-panel/)

**Panelists:** 
**Dr. Boxiong Tang** – Former Head of HEOR at Pfizer, Janssen, and BeiGene; Chair, ISPOR Asia HTA Consortium; a leading voice in shaping China’s HTA framework.  
**Ed Schoonveld** – Former Global Pricing Head at Wyeth, Eli Lilly, and BMS; Former Head of Value & Access Practice at ZS Associates; author of *The Price of Global Health*.  
**Kelly Ke** – Award-winning former senior advisor at Deloitte US Life Sciences practice; Founder, bizi LLC; Architect of NRDL+ Executive Debrief, interpreting regulatory signals and implementation dynamics shaping medicine access across China’s multi-layer coverage system.

---